Skip to main content

Table 2 Thematic analysis of cancer PACE meeting summaries

From: Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes

Themes Frequency (n = 45) Incorporated in CEE?
Characteristics of the disease: 40   
 Poor prognosis   30 ~
 Heavily symptomatic   24 ~
 Devastating impact on patient and family   19 x
 Patients are young   12 x
 Psychological impact on patient   10
Patient benefits of the drug: 45   
 Tolerability   31 ~
 Increase in overall survival   26
 Improved progression-free survival   21
 Issues with status quo treatments   19
 Productivity   18 x
 Value of extra time   17
 Normal life   17 ~
 Better symptom control   16
 Independence   16 ~
 Quality of life   15
 Reduces anxiety/gives hope   11 ~
 Trial evidence underestimates drug benefit   10
Drug options and treatment pathways: 45   
 Currently limited options   30
 Convenience   23 x
 Additional treatment option   14 ~
 Innovative therapy   13 x
 No recent development in this disease   10 x
General issues: 27   
 (Very) strong support for this medicine   14 x
 Should be made available in line with indication   11 x
Total comments   527  
  1. Includes themes mentioned in 10 or more PACE meeting summaries
  2. √ Explicitly incorporated in cost-effectiveness evaluation (CEE); ~ Partially or indirectly incorporated; x Not incorporated